A proposed solution to the clinical assessment of sarcoidosis: The sarcoidosis three-dimensional assessment instrument (STAI)

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1080-1087

  Judson, Marc A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; EVALUATION; FUNCTIONAL ASSESSMENT; HUMAN; INSTRUMENT VALIDATION; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; SARCOIDOSIS; SARCOIDOSIS THREE DIMENSIONAL ASSESSMENT INSTRUMENT; VALIDATION STUDY;

BONE DISEASES; DIAGNOSTIC TECHNIQUES AND PROCEDURES; EYE DISEASES; HUMANS; LIVER DISEASES; SARCOIDOSIS; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SPLENIC DISEASES;

EID: 33847024277     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.09.041     Document Type: Article

References (20)

1. American Thoracic Society/European Respiratory Society. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (RS) and the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) adopted by the ATS Board of Directors and the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
2. Yeager H., Rossman M.D., Baughman R.P., Teirstein A.S., Judson M.A., et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diff Lung Dis 22 (2005) 147-153
3. Judson M.A., Baughman R.P., Teirstein A.S., Terrin M.L., and Yeager H. ACCESS Research Group. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diff Lung Dis 16 (1999) 75-86
4. Judson M.A., and Baughman R.P. Sarcoidosis. In: Baughman R.P., DuBois R.M., and Lynch J.P. (Eds). Diffuse lung disease, a practical approach (2004), Arnold Publishers, London 109-129
5. Okumura W., Iwasaki T., Toyama T., et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 (2004) 1989-1998
6. Vignaux O., Dhote R., Duboe D., Blanche P., Dusser D., et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis. Chest 122 (2002) 1895-1901
7. Baughman. WASOG Task Force.
8. Judson M.A., Baughman R.P., Thompson B.W., Teirstein A.S., Terrin M.L., et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diff Lung Dis 20 (2003) 204-211
9. Wasfi Y.S., Rose C.S., Murphy J.R., Silveira L.J., Grutters J.C., Inoue Y., et al. A new tool to assess sarcoidosis severity. Chest 129 (2006) 1234-1245
10. Wertheim M.S., Mathers W.D., Suhler E.B., Wilson D.J., et al. Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy. Arch Ophthalmol 123 (2005) 274-276
11. Cox C.E., Donohue J.F., Brown C.D., Kataria Y.P., and Judson M.A. Health-related quality of life in persons with sarcoidosis. Chest 125 (2004) 997-1004
12. Judson M.A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 115 (1999) 1158-1165
13. 67Ga lung scans in assessing sarcoidosis. Experience in 14 research centers in seven different countries. Ann NY Acad Sci 465 (1986) 463-478
14. Studdy P.R., and James D.G. The specificity and sensitivity of serum angiotensin-converting enzyme in sarcoidosis and other diseases. Experiences in 12 centers in six different countries. In: Chertien J., Marsac J., and Saltiel J.C. (Eds). Sarcoidosis (1983), Pergamon Press, Paris 332-344
15. Thomas P.D., and Hunninghake G.W. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 135 (1987) 747-760
16. Finkel R., Teirstein A.S., Levine R., et al. Pulmonary function tests, serum angiotensin-converting enzyme levels, and clinical findings as prognostic indicators in sarcoidosis. Ann NY Acad Sci 465 (1986) 665-671
17. Baughman R.P., Fernandez M., Bosken C.H., Mantil F., and Hurtubise P. Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis: predicting response to therapy. Am Rev Respir Dis 129 (1984) 676-681
18. Laviolette M., La Forge J., Tennina S., and Boulet L.P. Prognostic value of bronchoalveolar lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest 100 (1991) 380-384
19. Gottlieb J.E., Israel H.L., Steiner R.M., et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 111 (1997) 623-631
20. Baughman R.P., Judson M.A., Teirstein A., Yeager H., Rossman M., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Q J Med 99 (2006) 307-315